Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones

Virology

Volumn 436, Issue 1, 2013, Pages 33-48

  Baalwa, Joshua ^a   Wang, Shuyi ^b   Parrish, Nicholas F ^b   Decker, Julie M ^c   Keele, Brandon F ^d   Learn, Gerald H ^b   Yue, Ling ^e   Ruzagira, Eugene ^f   Ssemwanga, Deogratius ^f   Kamali, Anatoli ^f   Amornkul, Pauli N ^g   Price, Matt A ^g   Kappes, John C ^c   Karita, Etienne ^e   Kaleebu, Pontiano ^f   Sanders, Eduard ^g   Gilmour, Jill ^g   Allen, Susan ^h   Hunter, Eric ^e   Montefiori, David C ^j   Haynes, Barton F ⁱ   Cormier, Emmanuel ^g   Hahn, Beatrice H ^b   Shaw, George M ^b   more..

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Alabama at Birmingham   (United States)

^d SAIC FREDERICK INC   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NONE

more..

Author keywords

HIV 1; HIV 1 subtype A; HIV 1 subtype D; HIV 1 transmission; Neutralizing antibodies; Single genome sequencing; Transmitted founder virus

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE D; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PRIORITY JOURNAL; RISK FACTOR; RWANDA; SEQUENCE ALIGNMENT; SEROLOGY; UNINDEXED SEQUENCE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CLONING, MOLECULAR; FEMALE; FOUNDER EFFECT; GENOME, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; OPEN READING FRAMES; RECEPTORS, CCR5; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872203837     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.10.009     Document Type: Article

References (73)

1. Aasa-Chapman M.M., Seymour C.R., Williams I., McKnight A. Novel envelope determinants for CCR3 use by human immunodeficiency virus. J. Virol. 2006, 80:10884-10889.
2. Abrahams M.R., Anderson J.A., Giorgi E.E., Seoighe C., Mlisana K., Ping L.H., Athreya G.S., Treurnicht F.K., Keele B.F., Wood N., Salazar-Gonzalez J.F., Bhattacharya T., Chu H., Hoffman I., Galvin S., Mapanje C., Kazembe P., Thebus R., Fiscus S., Hide W., Cohen M.S., Karim S.A., Haynes B.F., Shaw G.M., Hahn B.H., Korber B.T., Swanstrom R., Williamson C. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J. Virol. 2009, 83:3556-3567.
3. Baeten J.M., Chohan B., Lavreys L., Chohan V., McClelland R.S., Certain L., Mandaliya K., Jaoko W., Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 2007, 195:1177-1180.
4. Balasubramanian C., Chillemi G., Abbate I., Capobianchi M.R., Rozera G., Desideri A. Importance of V3 loop flexibility and net charge in the context of co-receptor recognition. A molecular dynamics study on HIV gp120. J. Biomol. Struct. Dyn. 2012, 29:1-13.
5. Bar K.J., Li H., Chamberland A., Tremblay C., Routy J.P., Grayson T., Sun C., Wang S., Learn G.H., Morgan C.J., Schumacher J.E., Haynes B.F., Keele B.F., Hahn B.H., Shaw G.M. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 2010, 84:6241-6247.
6. Bar K.J., Tsao C.Y., Iyer S.S., Decker J.M., Yang Y., Bonsignori M., Chen X., Hwang K.K., Montefiori D.C., Liao H.X., Hraber P., Fischer W., Li H., Wang S., Sterrett S., Keele B.F., Ganusov V.V., Perelson A.S., Korber B.T., Georgiev I., McLellan J.S., Pavlicek J.W., Gao F., Haynes B.F., Hahn B.H., Kwong P.D., Shaw G.M. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 2012, 8:e1002721.
7. Bhakta S.J., Shang L., Prince J.L., Claiborne D.T., Hunter E. Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Retrovirology 2011, 8:37.
8. Blish C.A., Nedellec R., Mandaliya K., Mosier D.E., Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007, 21:693-702.
9. Church J.D., Huang W., Mwatha A., Toma J., Stawiski E., Donnell D., Guay L.A., Mmiro F., Musoke P., Jackson J.B., Parkin N., Eshleman S.H. HIV-1 tropism and survival in vertically infected Ugandan infants. J. Infect. Dis. 2008, 197:1382-1388.
10. Coetzer M., Nedellec R., Salkowitz J., McLaughlin S., Liu Y., Heath L., Mullins J.I., Mosier D.E. Evolution of CCR5 use before and during coreceptor switching. J. Virol. 2008, 82:11758-11766.
11. de Souza M.S., Ratto-Kim S., Chuenarom W., Schuetz A., Chantakulkij S., Nuntapinit B., Valencia-Micolta A., Thelian D., Nitayaphan S., Pitisuttithum P., Paris R.M., Kaewkungwal J., Michael N.L., Rerks-Ngarm S., Mathieson B., Marovich M., Currier J.R., Kim J.H. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 2012, 188:5166-5176.
12. De Wolf F., Hogervorst E., Goudsmit J., Fenyo E.M., Rubsamen-Waigmann H., Holmes H., Galvao-Castro B., Karita E., Wasi C., Sempala S.D., et al. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO network for HIV isolation and characterization. AIDS Res. Hum. Retroviruses 1994, 10:1387-1400.
13. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., Hoxie J.A., Hahn B.H., Kwong P.D., Robinson J.E., Shaw G.M. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 2005, 201:1407-1419.
14. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303:2019-2022.
15. Dwivedi S.K., Sengupta S. Classification of HIV-1 sequences using profile hidden markov models. PLoS One 2012, 7:e36566.
16. Fiebig E.W., Wright D.J., Rawal B.D., Garrett P.E., Schumacher R.T., Peddada L., Heldebrant C., Smith R., Conrad A., Kleinman S.H., Busch M.P. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879.
17. Goonetilleke N., Liu M.K., Salazar-Gonzalez J.F., Ferrari G., Giorgi E., Ganusov V.V., Keele B.F., Learn G.H., Turnbull E.L., Salazar M.G., Weinhold K.J., Moore S., Letvin N., Haynes B.F., Cohen M.S., Hraber P., Bhattacharya T., Borrow P., Perelson A.S., Hahn B.H., Shaw G.M., Korber B.T., McMichael A.J. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 2009, 206:1253-1272.
18. Guindon S., Dufayard J.F., Lefort V., Anisimova M., Hordijk W., Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 2010, 59:307-321.
19. Guo X., Kameoka M., Wei X., Roques B., Gotte M., Liang C., Wainberg M.A. Suppression of an intrinsic strand transfer activity of HIV-1 Tat protein by its second-exon sequences. Virology 2003, 307:154-163.
20. Haaland R.E., Hawkins P.A., Salazar-Gonzalez J., Johnson A., Tichacek A., Karita E., Manigart O., Mulenga J., Keele B.F., Shaw G.M., Hahn B.H., Allen S.A., Derdeyn C.A., Hunter E. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009, 5:e1000274.
21. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
22. Huang W., Eshleman S.H., Toma J., Fransen S., Stawiski E., Paxinos E.E., Whitcomb J.M., Young A.M., Donnell D., Mmiro F., Musoke P., Guay L.A., Jackson J.B., Parkin N.T., Petropoulos C.J. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J. Virol. 2007, 81:7885-7893.
23. Isaacman-Beck J., Hermann E.A., Yi Y., Ratcliffe S.J., Mulenga J., Allen S., Hunter E., Derdeyn C.A., Collman R.G. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J. Virol. 2009, 83:8208-8220.
24. Jiang C., Parrish N.F., Wilen C.B., Li H., Chen Y., Pavlicek J.W., Berg A., Lu X., Song H., Tilton J.C., Pfaff J.M., Henning E.A., Decker J.M., Moody M.A., Drinker M.S., Schutte R., Freel S., Tomaras G.D., Nedellec R., Mosier D.E., Haynes B.F., Shaw G.M., Hahn B.H., Doms R.W., Gao F. Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J. Virol. 2011, 85:10669-10681.
25. Kaleebu P., French N., Mahe C., Yirrell D., Watera C., Lyagoba F., Nakiyingi J., Rutebemberwa A., Morgan D., Weber J., Gilks C., Whitworth J. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J. Infect. Dis. 2002, 185:1244-1250.
26. Kaleebu P., Nankya I.L., Yirrell D.L., Shafer L.A., Kyosiimire-Lugemwa J., Lule D.B., Morgan D., Beddows S., Weber J., Whitworth J.A. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J. Acquir. Immune Defic. Syndr. 2007, 45:28-33.
27. Kalia V., Sarkar S., Gupta P., Montelaro R.C. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation. J. Virol. 2003, 77:3634-3646.
28. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Nat. Acad. Sci. U.S.A 2008, 105:7552-7557.
29. Keele B.F., Li H., Learn G.H., Hraber P., Giorgi E.E., Grayson T., Sun C., Chen Y., Yeh W.W., Letvin N.L., Mascola J.R., Nabel G.J., Haynes B.F., Bhattacharya T., Perelson A.S., Korber B.T., Hahn B.H., Shaw G.M. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 2009, 206:1117-1134.
30. Khoja S., Ojwang P., Khan S., Okinda N., Harania R., Ali S. Genetic analysis of HIV-1 subtypes in Nairobi, Kenya. PLoS One 2008, 3:e3191.
31. Kiwanuka N., Laeyendecker O., Robb M., Kigozi G., Arroyo M., McCutchan F., Eller L.A., Eller M., Makumbi F., Birx D., Wabwire-Mangen F., Serwadda D., Sewankambo N.K., Quinn T.C., Wawer M., Gray R. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J. Infect. Dis. 2008, 197:707-713.
32. Kiwanuka N., Robb M., Laeyendecker O., Kigozi G., Wabwire-Mangen F., Makumbi F.E., Nalugoda F., Kagaayi J., Eller M., Eller L.A., Serwadda D., Sewankambo N.K., Reynolds S.J., Quinn T.C., Gray R.H., Wawer M.J., Whalen C.C. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J. Acquir. Immune. Defic. Syndr. 2010, 54:180-184.
33. Kuiken C., Foley B., Leitner T., Apetrei C., Hahn B., Mizrachi I., Mullins J., Rambaut A., Wolinsky S., Korber B.T. HIV sequence compendium 2011. Theor. Biol. Biophys. Group, L.A.N.L., NM, LA-U 2012, 10-3684. (Ed.).
34. Lambele M., Labrosse B., Roch E., Moreau A., Verrier B., Barin F., Roingeard P., Mammano F., Brand D. Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly. J. Virol. 2007, 81:125-140.
35. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
36. Lee H.Y., Giorgi E.E., Keele B.F., Gaschen B., Athreya G.S., Salazar-Gonzalez J.F., Pham K.T., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Hahn B.H., Shaw G.M., Korber B.T., Bhattacharya T., Perelson A.S. Modeling sequence evolution in acute HIV-1 infection. J. Theor. Biol. 2009, 261:341-360.
37. Levy D.N., Aldrovandi G.M., Kutsch O., Shaw G.M. Dynamics of HIV-1 recombination in its natural target cells. Proc. Nat. Acad. Sci. U.S.A 2004, 101:4204-4209.
38. Li H., Bar K.J., Wang S., Decker J.M., Chen Y., Sun C., Salazar-Gonzalez J.F., Salazar M.G., Learn G.H., Morgan C.J., Schumacher J.E., Hraber P., Giorgi E.E., Bhattacharya T., Korber B.T., Perelson A.S., Eron J.J., Cohen M.S., Hicks C.B., Haynes B.F., Markowitz M., Keele B.F., Hahn B.H., Shaw G.M. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 2010, 6:e1000890.
39. Li H., Stoddard M.B., Wang S., Blair L.M., Giorgi E.E., Parrish E.H., Learn G.H., Hraber P., Goepfert P.A., Saag M.S., Denny T.N., Haynes B.F., Hahn B.H., Ribeiro R.M., Perelson A.S., Korber B.T., Bhattacharya T., Shaw G.M. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog. 2012, 8:e1002880.
40. Lihana R.W., Khamadi S.A., Kiptoo M.K., Kinyua J.G., Lagat N., Magoma G.N., Mwau M.M., Makokha E.P., Onyango V., Osman S., Okoth F.A., Songok E.M. HIV type 1 subtypes among STI patients in Nairobi: a genotypic study based on partial pol gene sequencing. AIDS Res. Hum. Retroviruses 2006, 22:1172-1177.
41. Lole K.S., Bollinger R.C., Paranjape R.S., Gadkari D., Kulkarni S.S., Novak N.G., Ingersoll R., Sheppard H.W., Ray S.C. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J. Virol. 1999, 73:152-160.
42. Lu L., Zhu Y., Huang J., Chen X., Yang H., Jiang S., Chen Y.H. Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J. Biol. Chem. 2008, 283:16723-16731.
43. Mahlknecht U., Dichamp I., Varin A., Van Lint C., Herbein G. NF-κB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J. Leukoc. Biol. 2008, 83:718-727.
44. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 1995, 69:5087-5094.
45. Nedellec R., Coetzer M., Shimizu N., Hoshino H., Polonis V.R., Morris L., Martensson U.E., Binley J., Overbaugh J., Mosier D.E. Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J. Virol. 2009, 83:8353-8363.
46. Neuveut C., Scoggins R.M., Camerini D., Markham R.B., Jeang K.T. Requirement for the second coding exon of Tat in the optimal replication of macrophage-tropic HIV-1. J. Biomed. Sci. 2003, 10:651-660.
47. Ochsenbauer C., Edmonds T.G., Ding H., Keele B.F., Decker J., Salazar M.G., Salazar-Gonzalez J.F., Shattock R., Haynes B.F., Shaw G.M., Hahn B.H., Kappes J.C. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 2012, 86:2715-2728.
48. Palmer S., Kearney M., Maldarelli F., Halvas E.K., Bixby C.J., Bazmi H., Rock D., Falloon J., Davey R.T., Dewar R.L., Metcalf J.A., Hammer S., Mellors J.W., Coffin J.M. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43:406-413.
49. Parrish N.F., Wilen C.B., Banks L.B., Iyer S.S., Pfaff J.M., Salazar-Gonzalez J.F., Salazar M.G., Decker J.M., Parrish E.H., Berg A., Hopper J., Hora B., Kumar A., Mahlokozera T., Yuan S., Coleman C., Vermeulen M., Ding H., Ochsenbauer C., Tilton J.C., Permar S.R., Kappes J.C., Betts M.R., Busch M.P., Gao F., Montefiori D., Haynes B.F., Shaw G.M., Hahn B.H., Doms R.W. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4Β7. PLoS Pathog. 2012, 8:e1002686.
50. Pearson J.E., Krapivsky P., Perelson A.S. Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput. Biol. 2011, 7:e1001058.
51. Price M.A., Rida W., Mwangome M., Mutua G., Middelkoop K., Roux S., Okuku H.S., Bekker L.G., Anzala O., Ngugi E., Stevens G., Chetty P., Amornkul P.N., Sanders E.J. Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J. Acquir. Immune. Defic. Syndr. 2012, 59:185-193.
52. Price M.A., Wallis C.L., Lakhi S., Karita E., Kamali A., Anzala O., Sanders E.J., Bekker L.G., Twesigye R., Hunter E., Kaleebu P., Kayitenkore K., Allen S., Ruzagira E., Mwangome M., Mutua G., Amornkul P.N., Stevens G., Pond S.L., Schaefer M., Papathanasopoulos M.A., Stevens W., Gilmour J. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res. Hum. Retroviruses 2011, 27:5-12.
53. Provine N.M., Cortez V., Chohan V., Overbaugh J. The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant. Virology 2012, 427:25-33.
54. Quakkelaar E.D., van Alphen F.P., Boeser-Nunnink B.D., van Nuenen A.C., Pantophlet R., Schuitemaker H. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J. Virol. 2007, 81:8533-8542.
55. Redd A.D., Mullis C.E., Serwadda D., Kong X., Martens C., Ricklefs S.M., Tobian A.A., Xiao C., Grabowski M.K., Nalugoda F., Kigozi G., Laeyendecker O., Kagaayi J., Sewankambo N., Gray R.H., Porcella S.F., Wawer M.J., Quinn T.C. The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda. J. Infect. Dis. 2012, 206:267-274.
56. Rogers J.S., Swofford D.L. Multiple local maxima for likelihoods of phylogenetic trees: a simulation study. Mol. Biol. Evol. 1999, 16:1079-1085.
57. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., Heath L., Magaret C.A., Bose M., Bradfield A., O'Sullivan A., Crossler J., Jones T., Nau M., Wong K., Zhao H., Raugi D.N., Sorensen S., Stoddard J.N., Maust B.S., Deng W., Hural J., Dubey S., Michael N.L., Shiver J., Corey L., Li F., Self S.G., Kim J., Buchbinder S., Casimiro D.R., Robertson M.N., Duerr A., McElrath M.J., McCutchan F.E., Mullins J.I. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med 2011, 17:366-371.
58. Sacktor N., Nakasujja N., Skolasky R.L., Rezapour M., Robertson K., Musisi S., Katabira E., Ronald A., Clifford D.B., Laeyendecker O., Quinn T.C. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin. Infect. Dis. 2009, 49:780-786.
59. Sagar M., Laeyendecker O., Lee S., Gamiel J., Wawer M.J., Gray R.H., Serwadda D., Sewankambo N.K., Shepherd J.C., Toma J., Huang W., Quinn T.C. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J. Infect. Dis. 2009, 199:580-589.
60. Sagar M., Lavreys L., Baeten J.M., Richardson B.A., Mandaliya K., Chohan B.H., Kreiss J.K., Overbaugh J. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J. Virol. 2003, 77:12921-12926.
61. Salazar-Gonzalez J.F., Bailes E., Pham K.T., Salazar M.G., Guffey M.B., Keele B.F., Derdeyn C.A., Farmer P., Hunter E., Allen S., Manigart O., Mulenga J., Anderson J.A., Swanstrom R., Haynes B.F., Athreya G.S., Korber B.T., Sharp P.M., Shaw G.M., Hahn B.H. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82:3952-3970.
62. Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., Learn G.H., Giorgi E.E., Li H., Decker J.M., Wang S., Baalwa J., Kraus M.H., Parrish N.F., Shaw K.S., Guffey M.B., Bar K.J., Davis K.L., Ochsenbauer-Jambor C., Kappes J.C., Saag M.S., Cohen M.S., Mulenga J., Derdeyn C.A., Allen S., Hunter E., Markowitz M., Hraber P., Perelson A.S., Bhattacharya T., Haynes B.F., Korber B.T., Hahn B.H., Shaw G.M. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009, 206:1273-1289.
63. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84:1439-1452.
64. Simmonds P., Balfe P., Ludlam C.A., Bishop J.O., Brown A.J. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J. Virol. 1990, 64:5840-5850.
65. Ssemwanga D., Ndembi N., Lyagoba F., Bukenya J., Seeley J., Vandepitte J., Grosskurth H., Kaleebu P. HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res. Hum. Retroviruses 2012, 28:357-365.
66. Steckbeck J.D., Craigo J.K., Barnes C.O., Montelaro R.C. Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication. J. Biol. Chem. 2011, 286:27156-27166.
67. Tang J., Cormier E., Gilmour J., Price M.A., Prentice H.A., Song W., Kamali A., Karita E., Lakhi S., Sanders E.J., Anzala O., Amornkul P.N., Allen S., Hunter E., Kaslow R.A. Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J. Virol. 2011, 858894-858902.
68. Vasan A., Renjifo B., Hertzmark E., Chaplin B., Msamanga G., Essex M., Fawzi W., Hunter D. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin. Infect. Dis. 2006, 42:843-852.
69. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
70. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
71. Wilen C.B., Parrish N.F., Pfaff J.M., Decker J.M., Henning E.A., Haim H., Petersen J.E., Wojcechowskyj J.A., Sodroski J., Haynes B.F., Montefiori D.C., Tilton J.C., Shaw G.M., Hahn B.H., Doms R.W. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 2011, 85:8514-8527.
72. Wyss S., Dimitrov A.S., Baribaud F., Edwards T.G., Blumenthal R., Hoxie J.A. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J. Virol. 2005, 79:12231-12241.
73. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 2005, 79:1252-1261.